Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RN7SK pseudogene 243 is classified as a pseudogene of the RN7SK gene, which encodes a well-studied small nuclear RNA involved in the regulation of transcription elongation by RNA polymerase II[1]. Pseudogenes are generally nonfunctional sequences arising from gene duplications or retrotransposition events and typically do not produce functional products. While the RN7SK RNA itself plays essential roles in the regulation of gene expression and cellular homeostasis, including the assembly of the 7SK small nuclear ribonucleoprotein complex[3][5], there is no data indicating that RN7SKP243 is expressed, has biological function, or is a viable therapeutic target. RN7SKP243 is a genomic sequence; it is not a protein, enzyme, receptor, transporter, or established non-coding RNA with a known function. The functional analog (RN7SK), is a canonical lncRNA involved in transcriptional regulation, but the pseudogene RN7SKP243 is not catalogued as functional or as a drug target[1][6]. If your use case specifically requires canonical, functional biological targets, this entry should be excluded or flagged as problematic.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RN7SK pseudogene 243 (RN7SKP243).